Close Menu

This story has been updated to include comments from Illumina's investor call and a Piper Sandler research note.

NEW YORK – Illumina reported after the close of the market on Thursday that its second quarter 2020 revenues fell 25 percent year over year, primarily due to the impact of the COVID-19 pandemic on research customers.

For the three months ended June 30, 2020, Illumina recorded total revenues of $633 million, compared to $838 million compared a year ago, falling short of the consensus Wall Street Estimate of $697.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

Sep
24
Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
06
Sponsored by
10x Genomics

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure. 

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.